Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females between 18 and 65 years, inclusive, at time of Screening~* Females must be post-menopausal for more than 2 years or surgically sterile or practicing abstinence/specific forms of birth control~* Subject has never received antiviral treatment for hepatitis C infection~* Chronic HCV Genotype-1 infection prior to study enrollment~Exclusion Criteria:~* Positive test result for Hepatitis B surface antigen (HBsAg) or anti-Human Immunodeficiency virus antibody (HIV Ab)~* Females who are pregnant or plan to become pregnant, or breastfeeding~* Any current or past clinical evidence of cirrhosis~* Screening laboratory analyses that showing abnormal laboratory results~* Use of contraindicated medications within 2 weeks of dosing and subject with contraindication for telaprevir, pegIFN and RBV~* Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol~* Positive screen for drugs or alcohol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Arm A: 3-DAA + RBV in GT1a (Type: EXPERIMENTAL): ABT-450/r/ABT-267 150 mg/100 mg/25 mg once daily (QD) and ABT-333 250 mg twice daily (BID) and weight-based RBV for 12 weeks (3 direct-acting antivirals \[DAAs\] with RBV in GT1a)
- Arm B: TPV/PR in GT1a (Type: ACTIVE_COMPARATOR): Telaprevir (TPV) 750 mg every 8 hours (q8h) and pegIFN 180 µg/week and weight-based RBV (PR) for 12 weeks followed by an additional 12 or 36 weeks of pegIFN and weight-based RBV according to response guided therapy per the prescribing information for telaprevir (telaprevir with pegIFN/RBV in GT1a)
- Arm C: 3-DAA + RBV in GT1b (Type: EXPERIMENTAL): ABT-450/r/ABT-267 150 mg/100 mg/25 mg QD and ABT-333 250 mg BID and weight-based RBV for 12 weeks (3 DAAs with RBV in GT1b)
- Arm D: 3-DAA in GT1b (Type: EXPERIMENTAL): ABT-450/r/ABT-267 150 mg/100 mg/25 mg QD and ABT-333 250 mg BID for 12 weeks (3 DAAs without RBV in GT1b)
- Arm E: TPV/PR in GT1b (Type: ACTIVE_COMPARATOR): Telaprevir 750 mg q8h and pegIFN 180 µg/week and weight-based RBV for 12 weeks followed by an additional 12 or 36 weeks of pegIFN and weight-based RBV according to response guided therapy per the prescribing information for telaprevir (telaprevir with pegIFN/RBV in GT1b)

Based on this trial design, predict the completion outcome and termination type (if applicable).